XiaoMi-AI文件搜索系统
World File Search Systemstrengths
InstantsPlat：无界的稀疏视觉无姿势无姿势的高斯裂口在40秒内
虽然新颖的视图合成（NVS）在3D计算机视觉中取得了进步，但通常需要从密集的视点对摄像机内在和外部设备进行初始估计。这种预处理通常是通过结构 - 运动（SFM）管道来进行的，这是一种可以缓慢且不可靠的操作，尤其是在稀疏视图方案中，匹配的功能不足，无法进行准确的重建。In this work, we integrate the strengths of point-based representations (e.g., 3D Gaus- sian Splatting, 3D-GS) with end-to-end dense stereo mod- els (DUSt3R) to tackle the complex yet unresolved is- sues in NVS under unconstrained settings, which encom- passes pose-free and sparse view challenges.我们的框架工作，InstantsPlat，用3D-GS统一了密集的立体声先验，以构建稀疏场景的3D高斯大型场景 -
参考ID：5498572 -AccessData.fda.gov
Indications and Usage, Overactive Bladder in Adult Males with Benign Prostatic Hyperplasia (1.2) 12/2024 Contraindications (4) 10/2024 Warnings and Precautions, Angioedema (5.2) 10/2024 _________________ __________________ INDICATIONS AND USAGE GEMTESA is a beta-3 adrenergic agonist indicated for the treatment of: • overactive膀胱（OAB），成人急性尿失禁，紧迫性和尿频的症状。（1.1）•成人良性增生性增生的药理学治疗中，成年男性的急性尿失禁，紧迫性和尿频的症状过度活跃（OAB）。（BPH）（1.2）。______________ _______________剂量和给药•建议的剂量是每天口服一次75 mg片剂。（2.1）•用水吞咽整体。（2.1）•可以将片剂压碎并与苹果酱混合。(2.1) _____________ ______________ DOSAGE FORMS AND STRENGTHS Tablets: 75 mg (3) ____________________ ___________________ CONTRAINDICATIONS Do not use if prior hypersensitivity reaction to vibegron or any components of the product.（4）
教学术语
Lesson Plan – written instructions for a class session that includes a learning objective, introduction, teacher and student actions, assessments, materials and resources Linguistic Learning -learning style that includes an emphasis in reading and writing to measure standards Logical Learning- learning style in which learning takes place by the students ability to reason, problem solve, and think methodically M Maslow Hierarchy of Needs- Theorist , Abraham Maslow, stated that people prioritize needs and the most basic need is for physical survival before other needs can be met Multiple Intelligences – Howard Gardner's theory which categorizes learner strengths into the following categories: visual/spatial, logical/mathematical, naturalistic, linguistic, bodily/kinesthetic, interpersonal, and intrapersonal Modeling- being an example to follow Modifications (Also in Domain 2) - the act or instance of altering or changing instructional materials and/or strategies, activities and assessments
procrit处方信息
全部处方信息：内容*警告：ESA增加了死亡的风险，心肌梗塞，中风，静脉血栓栓塞，血管通道的血栓形成，肿瘤的进展或复发或复发1.1 1.1 1.1由于慢性肾脏疾病而导致的慢性肾脏疾病1.2因肿瘤患者而导致的1.2脑血症1. 3肌炎1.3 ANEMIA 1.3 ANEMIA 1.3 ANEMIA 1.3 ANEMIA 1.3 ANEMIA 1.3 ANEMIA 1.3 ANEMIA 1.3 ANEMIA 1.3，33例3的病毒疗法。 Allogeneic Red Blood Cell Transfusions in Patients Undergoing Elective, Noncardiac, Nonvascular Surgery 1.5 Limitations of Use 2 DOSAGE AND ADMINISTRATION 2.1 Important Dosing Information 2.2 Patients with Chronic Kidney Disease 2.3 Zidovudine-treated Patients with HIV Infection 2.4 Patients on Cancer Chemotherapy 2.5 Surgery Patients 2.6 Preparation and Administration 3 DOSAGE FORMS AND STRENGTHS 4 CONTRAINDICATIONS 5 WARNINGS AND PRECAUTIONS
2024财政年度国防授权法
401—End strengths for active forces ............................................... 1040 Sec.402—End strength level matters ..................................................... 1040 Subtitle B—Reserve Forces ............................................................................. 1040 Sec.411-选定储备金的末端优势................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................... 1040秒412—End strengths for Reserves on active duty in support of the Reserves ........................................................................................... 1040 Sec.413 - 军事技术人员的最终优势（双重地位）............................................................................................................................................................................................................414—Maximum number of reserve personnel authorized to be on active duty for operational support ................................................. 1041 Subtitle C—Authorization of Appropriations ................................................. 1041 Sec.421—Military personnel .................................................................... 1041 Legislative Provisions Not Adopted ................................................................ 1042 Extension of additional authority to vary Space Force end strength ... 1042 TITLE V—MILITARY PERSONNEL POLICY ..................................................... 1042 Subtitle A—Officer Policy ................................................................................................................................................... 1042秒501—Authorized strength: general and flag officers on active duty ......................................................................................................... 1042 Sec.505 - 海军现场促销配额的真实签名..........................................................................................................................................................................................................................................................................................................................................................................502 - 在美国国会大厦主治医师的现役期限的延期.....................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................503 - 授权晋升转移的权力是同一武装部队或其他武装部队之间的组成部分。。。。。。。。。。。。。。。。。。。。。。。。。。。。。。。。。。。。。。504 - 确定某些高级官员职位的任命条款的效果。506—Authority to increase the number of medical and dental officers recommended for promotion to certain grades ....................... 1043 Sec.507-遵守特殊选择审查委员会的某些官员的任命或提名。508-促销选择失败的影响......................................................................................................................................................................................................................................................................................................................................................................................................................................................................... 1044 sec。 509 - 有关海军陆战队网络空间运营官员的服务义务有关的事务。 509a-年级要求的时间........................................................................................................................................................................................................................................................................................................................................................................................................................................................... 1044 sec。 509b - 空间部队立法联络的建立。1044秒。 509c - 将授权的权力扩展到了被考虑晋升为少将的空间官员............................................................................................................................................................................................................................................................................................................................................................................................................................................................................................... 1045 sec。 511-为空军预备役政策委员会成员提供现役禁止...............................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................508-促销选择失败的影响......................................................................................................................................................................................................................................................................................................................................................................................................................................................................... 1044 sec。509 - 有关海军陆战队网络空间运营官员的服务义务有关的事务。509a-年级要求的时间........................................................................................................................................................................................................................................................................................................................................................................................................................................................... 1044 sec。509b - 空间部队立法联络的建立。1044秒。509c - 将授权的权力扩展到了被考虑晋升为少将的空间官员............................................................................................................................................................................................................................................................................................................................................................................................................................................................................................... 1045 sec。511-为空军预备役政策委员会成员提供现役禁止...............................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................509D—Briefing on number of general officers of the Space Force on active duty ......................................................................................... 1045 Subtitle B—Reserve Component Management .............................................. 1045 Sec.512 - 国民警卫队副总裁毕业.............................................. 1045
应用低级神经胶质瘤和相关
药物优势和可用的小瓶SIOP-LGG-2004感应卡铂强度10mg/ml； 5、15、45和60毫升长春新碱强度为1mg/ml的小瓶；在过敏或早期进展的情况下，1和2ML巩固卡铂的固结
combogesic -accessData.fda.gov
6 ADVERSE REACTIONS WARNING: HEPATOTOXICITY, 6.1 Clinical Trials Experience CARDIOVASCULAR RISK, AND 7 DRUG INTERACTIONS GASTROINTESTINAL RISK 8 USE IN SPECIFIC POPULATIONS 8.1 Pregnancy 1 INDICATIONS AND USAGE 8.2 Lactation 2 DOSAGE AND ADMINISTRATION 8.3 Females and Males of Reproductive Potential 3 DOSAGE FORMS AND STRENGTHS 8.4 Pediatric Use 4 CONTRAINDICATIONS 8.5 Geriatric Use 5 WARNINGS AND PRECAUTIONS 8.6 Use in Renal Disease 5.1 Hepatotoxicity 8.7 Use in Hepatic Disease 5.2 Cardiovascular Thrombotic Events 10 OVERDOSAGE 5.3 Gastrointestinal Bleeding, Ulceration, and 11 DESCRIPTION Perforation 12 CLINICAL PHARMACOLOGY 5.4 Hypertension 12.1 Mechanism of Action 5.5 Heart Failure and Edema 12.2 Pharmacodynamics 5.6 Renal Toxicity and Hyperkalemia 12.3药代动力学5.7过敏反应和其他超敏反应13非临床毒理学反应13.1癌变，诱变和生育能力损害5.8与阿司匹林的哮喘加剧14临床研究敏感性敏感性敏感性16提供/储存和处理方式。
处方信息| Korlym®（Mifepristone）300毫克平板电脑
WARNING: TERMINATION OF PREGNANCY 1 INDICATIONS AND USAGE 2 DOSAGE AND ADMINISTRATION 2.1 Testing Prior to and During KORLYM Administration 2.2 Adult Dosage 2.3 Dosing in Renal Impairment 2.4 Dosing in Hepatic Impairment 2.5 Concomitant Administration with CYP3A Inhibitors 3 DOSAGE FORMS AND STRENGTHS 4 CONTRAINDICATIONS 5 WARNINGS AND PRECAUTIONS 5.1 Adrenal Insufficiency 5.2 Hypokalemia 5.3阴道出血和子宫内膜变化5.4 QT间隔延长5.5经过皮质类固醇治疗治疗的疾病的恶化/恶化5.6使用强CYP3A抑制剂5.7肺炎孢子肠炎jiroveci感染5.8肺炎感染5.8 5.8临床互动反应的潜在互动6.1次临时试验6.1 porderbors nighter inders presseads 6.2 postrabs inders inders inders precign of 6.2 postrabs inders precign of 6.2 postrabs precign of 6.2 postrabs inders preckark of 6.2 postrack of 6.2。 CYP3A 7.2 CYP3A抑制剂7.3 CYP3A诱导剂
培训和技术协助-NJ.GOV
12月20日NJ环绕：价值与原则上午9:30 - 基于优势的护理计划 - CMO仅基于12月5日基于优势的护理计划：ISP＆FCP 9:30 AM - 12:30 PM
